Additional file 1 of Normal gastrointestinal mucosa at biopsy and subsequent cancer risk: nationwide population-based, sibling-controlled cohort study
Creators: name: Sun, Jiangwei
name: Fang, Fang
name: Olén, Ola
name: Song, Mingyang
name: Halfvarson, Jonas
name: Roelstraete, Bjorn
name: Khalili, Hamed
name: Ludvigsson, Jonas F.
Publisher: name: figshare
Year: 2022
Subjects: subject: Medicine
subject: Cell Biology
subject: Physiology
subject: FOS: Biological sciences
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Ecology
subject: Science Policy
subject: Immunology
subject: FOS: Clinical medicine
subject: Mathematical Sciences not elsewhere classified
subject: Cancer
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Computational Biology

description: Additional file 1: eTable 1. ICD-7 codes for cancer outcomes. eTable 2. Definitions of endoscopy, colectomy, and proctocolectomy. eTable 3. Incidence rate of cancer in individuals with a GI biopsy result of normal mucosa and their matched population references. eTable 4. Average risk of any cancer during follow-up in individuals with a GI biopsy result of normal mucosa and their matched references. eTable 5. Risk of specific cancers during follow-up in individuals with a GI biopsy result of normal mucosa and their matched references. eTable 6. Cumulative incidence and its difference of specific cancers during follow-up in individuals with a GI biopsy result of normal mucosa and their matched references. eTable 7. Sensitivity analyses for the risk of any cancer during follow-up in individuals with a GI biopsy result of normal mucosa and their matched references. eTable 8. Characteristics of individuals with a gastrointestinal (GI) biopsy result of normal mucosa and their siblings, a nationwide matched cohort study in Sweden, 1965-2016. eTable 9. Association between a GI biopsy result of normal mucosa and risk of any cancer, starting follow-up from 6 months vs. 1 year after biopsy. eFigure 1. Standardized cumulative incidence and 95% confidence intervals of any cancer in individuals with a GI biopsy result of normal mucosa (solid line and orange) and their matched references (dotted line and blue), stratified by age at cohort entry or calendar period of cohort entry. Follow-up was started 6 months after the biopsy. eFigure 2. Hazard ratio (HR) and 95% confidence intervals (CIs) of any cancer as a function of time since biopsy, comparing individuals with a GI biopsy result of normal mucosa with their matched references, stratified by calendar period of cohort entry. eFigure 3. Standardized cumulative incidence and 95% confidence intervals of specific cancers in individuals with a GI biopsy result of normal mucosa (solid line and orange) and their matched references (dotted line and blue). Follow-up was started 6 months after the biopsy. eFigure 4. Average hazard ratio (HR) and 95% confidence intervals (CIs) of specific cancers, comparing individuals with a GI biopsy result of normal mucosa with their matched references, stratified by biopsy location: upper (blue) or lower (orange) GI. Follow-up was started 6 months after the biopsy. eFigure 5. (A). Hazard ratio (HR) and 95% confidence intervals (CIs) of any cancer, comparing individuals with a GI biopsy result of normal mucosa with their siblings; (B). Standardized cumulative incidence and 95% confidence intervals of any cancer in individuals with normal mucosa (solid line and orange) and their siblings (dotted line and blue). Both were estimated from the flexible parametric model and follow-up was started 6 months after the biopsy.